Drug Trial Radar · NCT05353205
A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Last checked: Nov 19, 2026Latest source record: Apr 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 23, 2021
Primary completion
Dec 30, 2022
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It's a double-blind , randomized ,multi-center study. The purpose of this study is to explore the efficacy and safety of flumatinib 400mg once daily (QD) versus 600mg QD as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).
Conditions
- CML, Chronic Phase
Interventions
Flumatinib mesylate tablets (400mg)Drug
Flumatinib 400mg +Placebo for flumatinib are administered orally daily. Patients are randomized to flumatinib 400mg QD.
Flumatinib mesylate tablets (600mg)Drug
Flumatinib 600mg is administered orally daily. Patients are randomized to flumatinib 600mg QD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early molecular response(EMR) rate at 3 monthsTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology and Oncology, Harbin The First Hospital
Harbin, Hei Longjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.